J Korean Rheum Assoc.  2009 Mar;16(1):48-53. 10.4078/jkra.2009.16.1.48.

TNF Inhibitors and Uveitis in Ankylosing Spondylitis

• Kim HS
• Kim TJ
• Bae SC
• Yoo DH
• Jun JB
• Kim TH

• KMID: 2202141
• DOI: http://doi.org/10.4078/jkra.2009.16.1.48

Abstract

Uveitis is the most common extra-articular manifestation of ankylosing spondylitis, and this occurs in 30~50% of the patients with ankylosing spondylitis. The main symptoms of ankylosing spondylitis are usually highly responsive to TNF inhibitors, but the effects of TNF inhibitors on uveitis are inconsistent. We report here on sixteen cases of new onset uveitis during etanercept therapy in patients with ankylosing spondylitis and they had no histories of uveitis. The symptoms of ankylosing spondyltiis, other than the uveitis, were well controlled during etanercept therapy. Six patients had histories of infliximab therapy before undergoing etanercept therapy, and uveitis did not develop during this infliximab therapy. Uveitis can develop during the course of ankylosing spondylitis, yet there is a possibility of a temporal relationship between etanercept therapy and uveitis.

Keyword

Ankylosing spondylitis; TNF inhibitor; Uveitis

MeSH Terms

Antibodies, Monoclonal
Humans
Etanercept
Infliximab
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Spondylitis, Ankylosing
Uveitis
Antibodies, Monoclonal
Immunoglobulin G
Receptors, Tumor Necrosis Factor

Reference

References

1. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008; 67:955–9.

2. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002; 346:1349–56.

3. Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R, et al. Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. Ann Rheum Dis. 2002; 61(Suppl 3):iii51–60.

4. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002; 301:418–26.

5. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol. 2003; 87:925.

6. Monnet D, Moachon L, Dougados M, Brezin AP. Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis. Nat Clin Pract Rheumatol. 2006; 2:393–7.

7. Coates LC, McGonagle DG, Bennett AN, Emery P, Marzo-Ortega H. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. Ann Rheum Dis. 2008; 67:729–30.

8. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-ased study. Arthritis Rheum. 2007; 56:3248–52.

9. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006; 36:159–67.

10. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Downregulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum. 2003; 48:780–90.

11. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis. 2003; 62:561–4.

12. Dinarello CA. Differences between antitumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl. 2005; 74:40–7.

13. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003; 124:1774–85.

14. Rosenbaum JT. Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum. 2004; 50:3736–7.

15. Tiliakos AN, Tiliakos NA. Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary? J Rheumatol. 2003; 30:2727.